Vitiligo Clinical Trials

Find Vitiligo Clinical Trials Near You

A Phase 2, Randomized, Double-Blind, Placebo-controlled Proof-of-Concept Study to Evaluate the Efficacy and Safety of EI-001 in Patients With Nonsegmental Vitiligo

Status: Recruiting
Location: See all (6) locations...
Intervention Type: Other, Biological
Study Type: Interventional
Study Phase: Phase 2
SUMMARY

The primary purpose of this study is to evaluate whether the drug EI-001 can help improve vitiligo symptoms. EI-001 is a novel antibody drug that affects the immune system to decrease uncontrolled inflammation. EI-001 has been investigated in human cell cultures, animal studies, and in a Phase 1 healthy volunteer study. The results so far show that EI-001 is a tolerable and potential new treatment for immune diseases such as vitiligo.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 65
Healthy Volunteers: f
View:

• Able to understand and voluntarily sign the informed consent form (ICF).

• Male or female, aged 18-65 years at the time of consent.

• BMI 18-38 kg/m² and weight ≥ 40 kg at consent. Clinically diagnosed non-segmental vitiligo (NSV) for at least 3 months, and meets one of the following:

• Inadequate response to approved treatments:

• Topical therapy (e.g., corticosteroids, calcineurin inhibitors, or JAK inhibitors) ≥ 3 months,

• Phototherapy ≥ 6 months, or Oral therapy (e.g., corticosteroids, calcineurin inhibitors) ≥ 3 months.

• Or unable to use these treatments due to contraindications, intolerance, or unsuitability.

• Depigmentation extent meeting all of the following:

⁃ Facial BSA (F-BSA) ≥ 0.5%, Facial VASI (F-VASI) ≥ 0.5, Total BSA (T-BSA) between 5% and 60%, Total VASI (T-VASI) ≥ 5.

• Agree to discontinue all vitiligo treatments from screening until final follow-up.

• If not previously vaccinated against zoster, agree to complete vaccination before Day 1.

• Contraception

• Not applicable to females of non-childbearing potential (surgically sterile or postmenopausal ≥12 months, confirmed by FSH at screening).

Locations
United States
California
Marvel Clinical Research
RECRUITING
Huntington Beach
Florida
Skin Care Research, LLC
RECRUITING
Hollywood
Massachusetts
U Mass Chan Medical School
WITHDRAWN
Worcester
Ohio
Apex Clinical Research Center, LLC (Mayfield)
RECRUITING
Mayfield Heights
Texas
Center for Clinical Studies
RECRUITING
Houston
Other Locations
Taiwan
Linkou Chang Gung Memorial Hospital
RECRUITING
Taoyuan
Time Frame
Start Date: 2025-12-30
Estimated Completion Date: 2027-09-30
Participants
Target number of participants: 45
Treatments
Experimental: Drug: EI-001
Placebo_comparator: Drug: Placebo
Related Therapeutic Areas
Sponsors
Leads: Elixiron Immunotherapeutics (Hong Kong) Ltd.

This content was sourced from clinicaltrials.gov

Similar Clinical Trials